| Symbol | ROIV |
|---|---|
| Name | ROIVANT SCIENCES LTD. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 11-12 ST. JAMESS SQUARE,SUITE 1, 3RD FLOOR, LONDON, SW1Y 4LB, United Kingdom |
| Telephone | +44 2074003347 |
| Fax | — |
| — | |
| Website | https://www.roivant.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001635088 |
| Description | Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Additional info from NASDAQ: |
📋 Venker Eric (Officer) plans to sell 200K shares of Roivant Sciences Ltd. (at $35.74 each, total $7.1M) Filed: Aug 28, 2026 | ID: 000133
Read more(10% Negative) ROIVANT SCIENCES LTD. (ROIV) Announces Delay in reflected Trials for Dermatomyositis Due to Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreRoivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Read morePriovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Read moreJAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
Read morePulik Richard 🔴 sold 5.7K shares of Roivant Sciences Ltd. (ROIV) at $36.84 Transaction Date: Aug 20, 2026 | Filing ID: 034239
Read moreVenker Eric 🔴 sold 13.9K shares of Roivant Sciences Ltd. (ROIV) at $36.84 Transaction Date: Aug 20, 2026 | Filing ID: 034238
Read moreSukhatme Mayukh 🟡 adjusted position in 335.2K shares (3 derivative) of Roivant Sciences Ltd. (ROIV) at $37.30 ($14.9M) Transaction Date: Aug 19, 2026 | Filing ID: 034066
Read more📋 MAYUKH SUKHATME (Officer) plans to sell 145K shares of ROIVANT SCIENCES LTD. (at $36.48 each, total $5.3M) Filed: Aug 21, 2026 | ID: 008512
Read more📋 MAYUKH SUKHATME (Officer) plans to sell 18K shares of ROIVANT SCIENCES LTD. (at $37.30 each, total $653K) Filed: Aug 20, 2026 | ID: 008467
Read more| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| RVT-101 | DRUG | Phase PHASE3 | Alzheimer's Disease | COMPLETED | NCT02585934 |
| RVT-101 70 mg | DRUG | Phase PHASE2 | Dementia With Lewy Bodies | TERMINATED | NCT02928445 |
| RVT-101 35 mg tablets | DRUG | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02586909 |
| RVT-101 35 mg | DRUG | Phase PHASE2 | Dementia With Lewy Bodies | TERMINATED | NCT02928445 |
| Placebo | DRUG | Phase PHASE2 | Lewy Body Dementia | COMPLETED | NCT02640729 |
| Nelotanserin | DRUG | Phase PHASE2 | Lewy Body Dementia | COMPLETED | NCT02640729 |